Profile for European Patent Office Patent: 2410844
✉ Email this page to a colleague
| Country | SPC | SPC Expiration |
|---|---|---|
| Netherlands | 300858 | ⤷ Start Trial |
| Denmark | CA 2016 00069 | ⤷ Start Trial |
| Lithuania | PA2016048 | ⤷ Start Trial |
| Germany | 122017000001 | ⤷ Start Trial |
| Estonia | C20160050 | ⤷ Start Trial |
| Estonia | C20160050 00207 | ⤷ Start Trial |
| Sweden | 1690067-2 | ⤷ Start Trial |
US Patent Family Members and Approved Drugs for European Patent Office Patent: 2410844
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| ⤷ Start Trial | May 4, 2031 | Msd Sub Merck | ZEPATIER | elbasvir; grazoprevir |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
